RxDoctor Payments DataLook up a doctor →

Rafael Alba Yunen, MD

Critical Care Medicine · Brunswick, GANPI 1497901987

Payments from drug & device makers

$57,606in general payments, 2019–2025

Across 762 payments — averaging $75.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$14K
  • GSK$9K
  • Amgen$7K
  • Sanofi$7K
  • Intuitive Surgical$7K
  • Pulmonx Corporation$2K
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$6,09411%
  • Speaking & faculty fees$23,90041%
  • Travel & lodging$5,4729%
  • Food & beverage$16,02528%
  • Education$6,11511%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,606 in reported general payments places this provider in the 95th percentile of 265 critical care medicine providers in Georgia.

See all critical care medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$217,266
Medicare patients
520
Services billed
2,486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter849$748,503
TrikaftaElexacaftor/Tezacaftor/Ivacaft13$338,196
AdempasRiociguat23$316,687
Dupixent PenDupilumab65$245,772
TezspireTezepelumab-Ekko56$241,365
OpsumitMacitentan13$164,259
Breztri AerosphereBudesonide/Glycopyr/Formoterol187$139,633
Breo ElliptaFluticasone/Vilanterol214$108,486
ZemairaAlpha-1-Proteinase Inhibitor21$83,806
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr100$48,370
Spiriva RespimatTiotropium Bromide77$46,686
Stiolto RespimatTiotropium Br/Olodaterol Hcl70$42,862
EliquisApixaban43$36,465
SymbicortBudesonide/Formoterol Fumarate126$34,971
Incruse ElliptaUmeclidinium Bromide69$33,927

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$9,077$967,2961,349 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Airsupra, Bevespi Aerosphere$14,363$433,443401 claims
BayerAdempas$76$316,68723 claims
Actelion Pharmaceuticals US, Inc.Opsumit$223$164,25913 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$985$89,548147 claims
CSL BehringZemaira$97$83,80621 claims
PfizerEliquis$115$36,46543 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 265 critical care medicine providers in Georgia.

Other critical care medicine in Brunswick

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →